Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients
TOKYO, Nov 16, 2020 – (JCN Newswire) – Eisai Co., Ltd. announced that it has been received approval from the European Commission for the use of its in-house discovered and developed anti-epileptic agent (AED) Fycompa (generic name: perampanel) in the treatment of pediatric patients. This approval extends the use of Fycompa as adjunctive therapy for... » read more